Bruton's Tyrosine Kinase Inhibition for Patients with ITP

The pathophysiology of immune thrombocytopenia (ITP) includes peripheral platelet destruction as well as impaired platelet production. The list of available options to treat ITP continues to expand based on a better understanding of the pathophysiology of this condition. Despite increasing therapeutic options, some patients have multiple relapses or refractory disease. One potential treatment target includes inhibition of Bruton's tyrosine kinase (BTK), which can result in a decrease in autoantibody production as well as reduction in macrophage-induced phagocytosis in the spleen and liver. Here, investigators conducted an industry-sponsored, dose-finding, phase 1–2 study to evaluate the safety and efficacy of the BTK inhibitor rilzabrutinib…